Physician profile
Ryan Eid
NPI 1215464540
$4,841.85
in general payments reported to CMS, 2019-2025
24 companies · $34.00 in 2025
The $34.00 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $340 · 2023: $1,681 · 2024: $2,786 · 2025: $34.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460 · Education: $41.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,459.81 |
| Education | $41.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,044.93 | 2022-2024 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $532.53 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Biocryst US Sales Co., LLC | $391.17 | 2022-2024 | Orladeyo |
| Amgen INC. | $363.19 | 2022-2025 | Tezspire |
| Csl Behring | $332.32 | 2022-2024 | Hizentra, Haegarda |
| Genzyme Corporation | $292.68 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $250.33 | 2023-2024 | Cuvitru, Takhzyro, Hyqvia |
| Abbvie INC. | $245.69 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $238.25 | 2023-2024 | Dupixent |
| Pfizer INC. | $195.04 | 2023-2024 | |
| Pharming Healthcare, INC. | $190.02 | 2022-2024 | Ruconest |
| Novartis Pharmaceuticals Corporation | $140.57 | 2023-2024 | |
| Grifols USA, LLC | $125.51 | 2022-2024 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $115.29 | 2022-2024 | Xolair |
| Blueprint Medicines Corporation | $94.80 | 2023-2024 | Ayvakit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $62.10 | 2022-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $44.27 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $30.92 | 2024 | Dupixent |
| Dermavant Sciences, INC. | $28.96 | 2024 | Vtama |
| Greer Laboratories, INC. | $27.65 | 2024 | Palforzia |
| Hikma Pharmaceuticals USA | $27.16 | 2023-2024 | Ryaltris |
| Phadia US INC. | $24.39 | 2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.64 | 2023 | Spiriva Respimat |
| Bio Products Laboratory USA, INC. | $20.44 | 2023 | Coagadex, Gammaplex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Eid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.